Case Control Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 7, 2015; 21(13): 3904-3911
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3904
Table 1 Analysis of factors affecting rapid virologic response to pegylated interferon-α plus ribavirin combination therapy in patients infected with hepatitis C virus genotype 2
RVRnon-RVRRVR vs non-RVR (1: non-RVR/2: RVR)
Univariate analysisMultivariate analysis
P valueOR95%CIP value
Baseline factors
Demographic data
Number of patients11169
Gender (1:male/2:female)54/5731/380.8705
Age (yr)60 (18-76)60 (18-80)0.9623
Body weight (kg)59.4 (35.6-90.9)56.0 (37.0-104)0.5154
Body mass index (kg/m2)23.4 (17.1-31.2)22.8 (15.2-34.8)0.9645
Histological fibrosis of liver (F0/1/2/3/4/ND )15/45/18/13/13/172/24/9/6/17/11
(F0-3/F4)81/1341/170.0202
Prior interferon and ribavirin treatment response
Naïve/Relapse/Non response101/10/064/3/20.8577
Laboratory data
Genetic variation at rs8099917 (TT/TG or GG)87/2455/140.9800
HCV-RNA (log10IU/mL)5.5 (5.0-7.0)6.4 (5.0-7.3)< 0.00014.402.24-8.63 (per 1.0 log10IU/mL)< 0.0001
HCV Genotype (2a/2b/2a + 2b/ND)69/23/2/1729/34/2/40.0005
White blood cells (/μL)4800 (2400-10300)4700 (2000-10200)0.5170
Hemoglobin (g/dL)14.1(9.5-18.2)13.8 (9.3-16.9)0.1899
Platelets (× 104/μL)17.1 (4.8-34.1)16.6 (5.5-34.1)0.7993
Aspartate aminotransferase (IU/L)48 (16-317)48 (13-455)0.6753
Alanine aminotransferase (IU/L)57 (10-361)56 (9-356)0.9699
Gamma-glutamyl-transpeptitase (IU/L)43 (7-719)48 (9-331)0.7526
Albumin (g/dL)4.1 (3.2-5.0)4.0 (2.9-4.8)0.00290.130.04-0.42 (per 1.0 g/dL)0.0006
Fasting total cholesterol (mg/dL)170 (118-265)173 (106-270)0.8155
Fasting low density lipoprotein-cholesterol (mg/dL)99 (45-158)103 (40-181)0.4186
Fasting plasma glucose (mg/dL)99 (76-221)100 (76-320)0.2002
Homeostasis model assessment-Insulin Resistance1.59 (0.56-10.83)1.38 (0.79-6.88)0.4722
Alpha-fetoprotein (ng/mL)4.7 (1.6-193.6)5.0 (1.0-130)0.4101
Table 2 Analysis of factors affecting sustained virologic response in non-rapid virologic response hepatitis C virus genotype 2 patients treated with 36 or 48-wk pegylated interferon-α plus ribavirin combination therapy
SVRnon-SVRSVR vs non-SVR (1: non-SVR/2: SVR)
Univaritate analysisMultivaritate analysis
P valueOR95%CIP value
Baseline factors
Demographic data
Number of patients5019
Gender (1:male/2:female)20/3011/80.2873
Age (yr)60.5 (18-80)53 (39-73)0.2341
Body weight (kg)55.0 (37.0-101.0)64.0 (44.0-104.0)0.1563
Body mass index (kg/m2)22.8 (15.2-32.8)22.8 (18.8-34.8)0.2426
Histological fibrosis of liver (F0/1/2/3/4/ND)11/18/6/6/10/91/6/3/0/7/2
(F0-3/F4)31/1010/70.2050
Prior interferon and ribavirin treatment response
Naïve/Relapse/Non response46/3/118/0/10.8933
Laboratory data
Genetic variation at rs8099917 (TG or GG/TT)6/448/110.01465.87 (1; TG or GG/ 2; TT)1.62-21.220.0059
HCV-RNA (Log10IU/mL)6.3 (5.0-7.3)6.4 (5.0-7.2)0.6064
HCV Genotype (2a/2b/2a + 2b/ND)21/24/2/38/10/0/10.8156
White blood cells (/μL)4700 (2800-7800)5550 (2000-10200)0.3001
Hemoglobin (g/dL)13.8 (11.0-16.9)13.75 (11.0-16.8)0.9279
Platelets (× 104/μL)16.6 (6.0-34.1)16.55 (6.1-29.7)0.9834
Aspartate aminotransferase (IU/L)54 (15-455)32 (13-264)0.0751
Alanine aminotransferase (IU/L)59 (12-356)36.5 (9-231)0.1866
Gamma-glutamyl-transpeptitase (IU/L)49 (9-292)47 (11-331)0.9237
Albumin (g/dL)4.0 (2.9-4.8)3.9 (3.1-4.7)0.5738
Fasting total cholesterol (mg/dL)172 (108-256)178 (106-270)0.6894
Fasting low density lipoprotein-cholesterol (mg/dL)102 (54-177)110 (40-181)0.9647
Fasting plasma glucose (mg/dL)98.5 (76-320)103.5 (93-158)0.1554
Homeostasis model assessment-Insulin Resistance1.36 (0.78-6.78)1.44 (1.19-5.39)0.3151
Alpha-fetoprotein (ng/mL)5.0 (1.0-96.0)5.0 (2.0-130)0.8593
On-treatment factors
Treatment
Adherence of Peg-IFN (%)277.1 (62.5-100.0)91.4 (66.0-104.6)0.0936
Adherence of RBV (%)275.0 (56.8-100.0)86.1 (86.1-94.4)0.0457
Duration of treatment (wk)37 (36-48)48 (36-48)0.1449